Related Experiment Video
Updated: Feb 20, 2026
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
12.3K
Emerging Therapies for Congestive Heart Failure
1Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Clinical Pharmacology and Therapeutics
|October 19, 2017
Summary
Stem cell therapy offers a promising new approach for heart failure with reduced ejection fraction by regenerating contractile tissue. This innovative treatment aims to improve cardiac performance and reverse adverse remodeling in patients with this condition.
Area of Science:
- Cardiology
- Regenerative Medicine
- Biomedical Engineering
Background:
- Despite advances in treating atherosclerotic heart disease, symptomatic heart failure with reduced ejection fraction (HFrEF) has a poor prognosis.
- Current treatments primarily address neurohormonal activation, not the core issue of lost cardiac contractile capacity in HFrEF.
Purpose of the Study:
- To review the potential of stem cell therapies for treating heart failure with reduced ejection fraction.
- To discuss the current status of clinical trials and future directions in this field.
Main Methods:
- Review of existing literature on stem cell therapies for cardiovascular diseases.
- Analysis of current clinical trial data and outcomes for stem cell treatments in HFrEF patients.
Main Results:
- Stem cell therapy demonstrates potential to regenerate functional cardiac tissue, addressing the contractile deficit in HFrEF.
- Regeneration of contractile tissue may normalize left ventricular dimensions and improve cardiac performance.
- This approach could reverse negative remodeling, thereby preventing progressive dysfunction and cardiogenic shock.
Conclusions:
- Stem cell therapy holds significant promise for improving outcomes in patients with heart failure with reduced ejection fraction.
- Further clinical development is crucial to establish the efficacy and safety of stem cell treatments for HFrEF.
- The field is advancing, with ongoing research poised to refine stem cell applications for cardiac regeneration.
More Related Videos
08:24Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
7.5K
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
12.5K
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
428
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
428
01:30Heart Failure V: Medical Management
388
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
388
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:29Cardiomyopathy V: Interprofessional Care
501
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
501
01:30Cardiomyopathy II: Dilated Cardiomyopathy
622
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
622